Confidential Materials omitted and filed separately with the Securities and
Exchange Commission. Asterisks denote omissions.
Exhibit 10.1
FIRST AMENDMENT TO LICENSE AGREEMENT
BY AND BETWEEN
BOSTON LIFE SCIENCES, INC.
AND
BIOAXONE THERAPEUTIC INC.
This first Amendment to the License Agreement (the "License") between Boston
Life Sciences, Inc. ("BLSI") and BioAxone Therapeutic, Inc. ("BA") dated as of
December 28, 2006 is made effective as of March 23, 2007.
For good and valuable consideration BLSI and BA hereby agree that the Licensed
Patent Rights described in Section 1.34 of the License and the therein
referenced Exhibit B is amended to include the following addition to Table 1 of
said Exhibit B:
Country Application Number Filing Date Patent Number Status Title
------- ------------------ ----------- ------------- ------ -----
[**] [**] [**] [**] [**] [**]
The parties further agree that said Table 1 of said Exhibit B is updated as
follows for purposes of clarification:
Country Application Number Filing Date Patent Number Status Title
------- ------------------ ----------- ------------- ------ -----
[**] [**] [**] [**] [**] [**]
REPLACE ABOVE WITH:
[**] [**] [**] [**] [**] [**]
IN WITNESS WHEREOF, the parties have executed this First Amendment as of the
date first set forth above.
BOSTON LIFE SCIENCES, INC.
By /s/ Xxxxxxx X. Xxxx
----------------------------------
Title EVP & CFO
BIOAXONE THERAPEUTIC INC.
By /s/ Xxxxx Xxxx
----------------------------------
Title President & CEO
